STOCK TITAN

AGILE THERAPEUTICS INC - AGRX STOCK NEWS

Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.

Company Overview

Agile Therapeutics Inc. (AGRX) is a dedicated women's healthcare company committed to addressing the unique health needs of modern women. Specializing in advanced transdermal drug delivery and contraceptive innovation, the company has developed products that offer women a flexible alternative to daily contraceptive pills. By harnessing its proprietary Skinfusion® technology, Agile Therapeutics delivers a non-daily, once-weekly prescription contraceptive patch that provides ease of use and improved patient adherence.

Innovative Technology and Product Focus

Central to Agile Therapeutics’ approach is its commitment to transforming women’s healthcare through innovation. The company’s lead product, Twirla®, is a combined hormonal contraceptive patch formulated using state-of-the-art transdermal technology. This system is designed to support efficient drug delivery, optimize patch adhesion, and enhance wearability, ensuring that women have a reliable and convenient contraception option without the burden of daily medication regimens.

Operational Excellence and Market Position

Agile Therapeutics operates at the intersection of biotechnology and patient-centric healthcare solutions. The company’s business model is built around leveraging its proprietary technologies to develop products that directly address the healthcare needs of women. By focusing on a specific niche in the contraceptive market, Agile Therapeutics has positioned itself as a key player in advancing non-daily contraceptive methods. Its strategic focus on innovation, controlled operating expenses, and collaborative partnerships underscores its commitment to sustainability and growth within the competitive healthcare landscape.

Commitment to Quality and Patient-Centric Solutions

At its core, Agile Therapeutics is driven by an unyielding focus on quality and patient safety. The design and development of its products, including Twirla®, are underpinned by rigorous clinical research and regulatory review. The company continually refines its product offerings to ensure that women receive a safe, effective, and convenient contraceptive option that meets modern lifestyle needs while ensuring adherence to high standards of medical care.

Industry Relevance and Competitive Landscape

Operating within the broader biotechnology and pharmaceutical sectors, Agile Therapeutics distinguishes itself by targeting a specific need within women’s healthcare. In a market where patient convenience, adherence, and minimized regimen complexity are paramount, the company’s focus on non-daily delivery systems sets it apart from traditional daily pill-based contraceptives and longer-acting methods. Its innovative approach and distinct value proposition highlight its relevancy and expertise in the competitive landscape, offering investors a clear insight into its business model and operational strategy.

Frequently Asked Questions

  • What is the core business of Agile Therapeutics Inc.?
    Agile Therapeutics focuses on creating innovative, non-daily contraceptive solutions designed to address the unique health needs of modern women through advanced transdermal technology.
  • What makes Twirla® unique?
    Twirla® is a once-weekly combined hormonal contraceptive patch that utilizes the proprietary Skinfusion® platform to optimize patch adhesion and provide a convenient alternative to daily pills.
  • How does Agile Therapeutics generate revenue?
    The company’s revenue model is primarily centered on the development, manufacturing, and commercialization of its prescription contraceptive products, supported by strategic partnerships and controlled operating expenses.
  • What role does transdermal technology play in its products?
    Transdermal technology is fundamental to Agile’s approach, enabling effective and controlled drug delivery through the skin, which enhances patient compliance and convenience.
  • How is the company positioned within the competitive pharmaceutical landscape?
    Agile Therapeutics differentiates itself by focusing on patient-centric, non-daily contraceptive solutions that fill a gap in women’s healthcare, thereby securing a niche within the broader biotech and pharmaceutical sectors.
  • What are the key advantages of Agile’s business model?
    The company’s model leverages proprietary technology for innovative product development, emphasizes operational efficiency, and builds strategic partnerships to enhance market reach and sustainability.
Rhea-AI Summary
Agile Therapeutics, Inc. commends the Biden-Harris Administration for their continued commitment to reproductive health, including increasing access to no-cost contraception. The new guidance released by the Departments of Labor, Health and Human Services, and the Treasury outlines a new pathway for plans and issuers to cover a broader range of FDA-approved contraceptive drugs and certain devices at no cost. This comes after President Biden's Executive Order in June 2023, directing the Secretaries to ensure comprehensive contraceptive care coverage without cost-sharing for enrollees, participants, and beneficiaries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
-
Rhea-AI Summary
Agile Therapeutics, Inc. (Nasdaq: AGRX) is commending House Committee on Oversight and Accountability Ranking Member Jamie Raskin for a new report on contraception coverage gaps, following several months of activity by the Biden Administration and lawmakers to strengthen access to contraception. The report could potentially eliminate financial barriers for contraceptive products like Twirla® for 49 million women.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.85%
Tags
none
-
Rhea-AI Summary
Agile Therapeutics, Inc. (AGRX) reported a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ, its birth control patch. The company also aims to achieve at least $25 million in full-year 2023 revenue and be cash flow positive from operations in the first quarter of 2024. Agile's Chair and CEO, Al Altomari, highlighted the company's achievements in net revenue, Twirla demand, factory sales, and gross margin. The company expects further growth from expanding its customer bases, boosting non-retail customer networks, and advancing Twirla through telemedicine platforms. Maxim Group recently upgraded its investment rating for Agile to buy from hold, setting a 12-month price target of $5.00, representing a 150% upside potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
Rhea-AI Summary
Agile Therapeutics, Inc. (Nasdaq: AGRX) reports a 21% increase in net revenue to $6.7 million in Q3 2023, with a gross margin growth to 63%. The company reaffirms its expected full-year 2023 net revenue of at least $25 million and anticipates positive cash flow from operations in Q1 2024. Management will host a conference call on November 9, 2023, at 8:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
-
Rhea-AI Summary
Agile Therapeutics, Inc. will report its third quarter 2023 financial results on November 9, 2023. A live conference call and webcast will be held at 8:30 a.m. ET to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
conferences earnings
-
Rhea-AI Summary
Agile Therapeutics grants inducement award to new CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
Rhea-AI Summary
Maxim Group upgrades Agile Therapeutics Inc. (NASDAQ:AGRX) to a 'buy' rating with a one-year price target of $5, nearly 180% increase from current level. Twirla sales accelerating significantly in 2Q23, expected to continue. Nurx partnership expands retail channel presence. 2023 revenue estimate increased to $25.3M, 2024 estimate to $42.9M. Gross margins expected to expand to 70% in 4Q23. Financing overhang but breakeven could come by 1H24. Upgrade to Buy, establishing a 12-month price target of $5.00.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
none
-
Rhea-AI Summary
Agile Therapeutics to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
conferences
-
Rhea-AI Summary
Agile Therapeutics (NASDAQ:AGRX) reported significant growth in revenue from its birth control patch, Twirla, in its second-quarter financial results. Net revenue from Twirla reached $5.5 million, a 44% increase from the previous quarter and a 159% increase from Q2 2022. Demand for the patch rose 158% year over year, contributing to the triple-digit revenue growth. Twirla factory sales were also up 42% from the previous quarter and 188% year over year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
none
Rhea-AI Summary
Agile Therapeutics, Inc. (Nasdaq: AGRX) reported second quarter 2023 net revenue of $5.5 million, a 44% increase from the first quarter 2023. Twirla demand and factory sales also saw significant growth. Gross margin grew to 58% in the second quarter 2023. The company reaffirmed its expected full year 2023 net revenue in the range of $25-$30 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.2%
Tags

FAQ

What is the current stock price of AGILE THERAPEUTICS (AGRX)?

The current stock price of AGILE THERAPEUTICS (AGRX) is $1.51 as of February 7, 2025.

What is the market cap of AGILE THERAPEUTICS (AGRX)?

The market cap of AGILE THERAPEUTICS (AGRX) is approximately 10.4M.

What is Agile Therapeutics Inc.?

Agile Therapeutics Inc. is a women's healthcare company focused on developing non-daily contraceptive solutions using advanced transdermal technology.

How does Twirla® differ from traditional contraceptives?

Twirla® is a once-weekly prescription patch that offers a convenient, non-daily alternative to traditional daily pills by utilizing proprietary Skinfusion® technology.

What is the significance of the Skinfusion® platform?

Skinfusion® is Agile's proprietary transdermal patch technology that ensures optimal drug delivery, improved adhesion, and enhanced patient wearability.

What market need does Agile Therapeutics address?

The company addresses the unmet needs of women seeking convenient and effective contraceptive options that free them from the daily routine of pill administration.

How is Agile positioned within the biotechnology sector?

Agile Therapeutics occupies a unique niche in the biotechnology sector by focusing on innovative, patient-centric contraceptive solutions that blend advanced technology with clinical efficacy.

What are the core elements of Agile’s business model?

The business model centers on leveraging proprietary technology to develop high-quality contraceptive products, maintaining operational efficiency, and fostering strategic partnerships in the healthcare industry.
AGILE THERAPEUTICS INC

Nasdaq:AGRX

AGRX Rankings

AGRX Stock Data

10.43M
5.14M
9.7%
16.02%
7.49%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Princeton